Literature DB >> 22963909

Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms.

Luca Miele1, Giovanni Cammarota, Vittoria Vero, Simona Racco, Consuelo Cefalo, Giuseppe Marrone, Maurizio Pompili, Gianlodovico Rapaccini, Alessandro Bianco, Raffaele Landolfi, Antonio Gasbarrini, Antonio Grieco.   

Abstract

BACKGROUND: Gastro-oesophageal reflux symptoms are usually reported by patients with obesity and metabolic syndrome. Aim of this study was to assess the prevalence and clinical characteristics of gastro-oesophageal reflux symptoms in subjects with non-alcoholic fatty liver disease.
METHODS: Cross-sectional, case-control study of 185 consecutive patients with non-alcoholic fatty liver disease and an age- and sex-matched control group of 112 healthy volunteers. Participants were interviewed with the aid of a previously validated questionnaire to assess lifestyle and reflux symptoms in the 3 months preceding enrolment. Odds ratios were determined before and after adjustment for body mass index, increased waist circumference, physical activity, metabolic syndrome and proton pump inhibitors and/or antiacid medication.
RESULTS: The prevalence of heartburn and/or regurgitation and of at least one of gastro-oesophageal reflux symptoms was significantly higher in the non-alcoholic fatty liver disease group. Non-alcoholic fatty liver disease subjects were associated to higher prevalence of heartburn (adjusted odds ratios: 2.17, 95% confidence intervals: 1.16-4.04), regurgitation (adjusted odds ratios: 2.61, 95% confidence intervals: 1.24-5.48) and belching (adjusted odds ratios: 2.01, 95% confidence intervals: 1.12-3.59) and had higher prevalence of at least one GER symptom (adjusted odds ratios: 3.34, 95% confidence intervals: 1.76-6.36).
CONCLUSION: Non-alcoholic fatty liver disease is associated with a higher prevalence of gastro-oesophageal reflux symptoms.
Copyright © 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22963909     DOI: 10.1016/j.dld.2012.08.005

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  9 in total

1.  Nonalcoholic Fatty Liver Disease Is Associated with Increased Risk of Reflux Esophagitis.

Authors:  Hyo-Joon Yang; Yoosoo Chang; Soo-Kyung Park; Yoon Suk Jung; Jung Ho Park; Dong Il Park; Yong Kyun Cho; Seungho Ryu; Chong Il Sohn
Journal:  Dig Dis Sci       Date:  2017-10-23       Impact factor: 3.199

2.  Metabolic Dysfunction-Associated Fatty Liver Disease Increases the Risk of Gastroesophageal Reflux Symptoms.

Authors:  Yuan He; Zhi-Jun Duan; Cheng-Fang Wang; Yu-Shan Wei; Ming-Xu Cai
Journal:  Diabetes Metab Syndr Obes       Date:  2022-01-20       Impact factor: 3.168

3.  Noninvasive Prediction of Erosive Esophagitis Using a Controlled Attenuation Parameter (CAP)-Based Risk Estimation Model.

Authors:  Hyunsoo Chung; Young Eun Chon; Seung Up Kim; Sang Kil Lee; Kyu Sik Jung; Kwang-Hyub Han; Chae Yoon Chon
Journal:  Dig Dis Sci       Date:  2015-10-06       Impact factor: 3.199

4.  Implication of gut microbiota in nonalcoholic fatty liver disease.

Authors:  Jerome Boursier; Anna Mae Diehl
Journal:  PLoS Pathog       Date:  2015-01-27       Impact factor: 6.823

Review 5.  Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: A meta-analysis.

Authors:  Karn Wijarnpreecha; Panadeekarn Panjawatanan; Charat Thongprayoon; Veeravich Jaruvongvanich; Patompong Ungprasert
Journal:  Saudi J Gastroenterol       Date:  2017 Nov-Dec       Impact factor: 2.485

6.  Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus.

Authors:  Cristina Llorente; Peter Jepsen; Tatsuo Inamine; Lirui Wang; Sena Bluemel; Hui J Wang; Rohit Loomba; Jasmohan S Bajaj; Mitchell L Schubert; Masoumeh Sikaroodi; Patrick M Gillevet; Jun Xu; Tatiana Kisseleva; Samuel B Ho; Jessica DePew; Xin Du; Henrik T Sørensen; Hendrik Vilstrup; Karen E Nelson; David A Brenner; Derrick E Fouts; Bernd Schnabl
Journal:  Nat Commun       Date:  2017-10-16       Impact factor: 14.919

7.  Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease.

Authors:  Amandeep Singh; Rajat Garg; Nan Lan; Mohamed Tausif Siddiqui; Mohit Gupta; Naim Alkhouri
Journal:  Indian J Gastroenterol       Date:  2020-11-21

8.  Fatty liver disease and the risk of erosive oesophagitis in the Korean population: a cross-sectional study.

Authors:  Ja Sung Choi; Hee Man Kim; Yun-Jung Yang; Sangheun Lee; Seok-Hoo Jeong; Ki Jun Han
Journal:  BMJ Open       Date:  2019-01-30       Impact factor: 2.692

Review 9.  Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs.

Authors:  Wataru Tomeno; Kento Imajo; Takuya Takayanagi; Yu Ebisawa; Kosuke Seita; Tsuneyuki Takimoto; Kanami Honda; Takashi Kobayashi; Asako Nogami; Takayuki Kato; Yasushi Honda; Takaomi Kessoku; Yuji Ogawa; Hiroyuki Kirikoshi; Yasunari Sakamoto; Masato Yoneda; Satoru Saito; Atsushi Nakajima
Journal:  Diagnostics (Basel)       Date:  2020-11-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.